Purpose: To test the feasibility of a cell therapy approach to treat corneal endothelial (CE) disorders using an in vitro model of human corneal decompensation.
H
uman corneal endothelial cells (hCECs) lack the selfrenewal potential because of being arrested in the G1 phase of the cell cycle, 1, 2 which is mediated by TGF-b and contact inhibition. 3, 4 Therefore, current treatments for corneal endothelial (CE) disorders rely on cadaveric human donor corneal transplantation for visual rehabilitation. 5 Transplantation techniques, such as Penetrating Keratoplasty (PK) and Descemet's Stripping Automated Endothelial Keratoplasty (DSEAK), have resulted in lowering of visual thresholds for surgical intervention with a consequent increase in demand for eye bank services across the world. Consequently, cell therapy research has gained popularity to explore solutions that could replace corneal transplantation and achieve rehabilitation of patients with severe CE disorders. The cell therapy approach for treating corneal blindness has been undertaken in a variety of animal models, such as rabbit, [6] [7] [8] [9] [10] [11] [12] [13] rat, 14, 15 primate, 16, 17 feline, [18] [19] [20] or ex vivo porcine eyes. 21 The rabbit and rat have been documented as species whose corneal endothelium has the capacity to renew itself through proliferation, 22, 23 whereas primates and cats seem to possess a limited self-renewal potential similar to that of humans. 22, 24 Because the human corneal endothelium lacks proliferative capacity, it would be more beneficial to use a model, which will make any data generated with it more clinically relevant.
A number of studies have also explored the potential of hCEC seeding directly on cadaveric human corneas [25] [26] [27] [28] [29] [30] [31] or have investigated the use of decellularized human corneal stroma 32 or human stromal lamellae as carriers for hCEC transplantation 33 and showed positive effects on diminishing corneal edema and restoring normal corneal thickness. In addition, if such research is undertaken on cadaveric human corneas, it could partly overcome the species bias inherent in using animal models. Thus, in this study, we have established an in vitro human model of CE decompensation by surgically removing the Descemet membrane (DM)/endothelium complex from cadaveric human donor corneas. These decompensated corneas were then used as a test model for cell transplantation of primary and in vitro cultured hCECs to the posterior corneal stroma.
MATERIALS AND METHODS

Cadaveric Human Donor Corneas
Human donor corneas (n = 22, Table 1 ) for this study were procured from the national eye banks of the United Kingdom, with consent for research, and the project was approved by Anglia Ruskin University Research Ethics committee (RESC080). The experiments were conducted in a Human Tissue Authority-approved research facility. The study adhered to the principles in the Declaration of Helsinki. None of the tissue donors were from a vulnerable population, and all donors or next of kin provided written informed consent for the use of corneas for research purposes. The corneas were stored in Eagle minimum essential medium supplemented with 2% fetal bovine serum (FBS) at 37°C. Age of all the donor corneas ranged between 29 and 89 years, with a mean age of 63 6 16 years. The period of storage before experimentation for all corneas ranged from 29 to 60 days, with a mean of 43 6 12 days.
CE Decompensation Model
Removing the DM/endothelium complex was done as follows in group 2 corneas to establish corneal stromal decompensation. The corneas were placed with the endothelial side facing upward on a trephine base (Coronet; Network medical Ltd, United Kingdom) and were stained for 30 seconds with 0.05% trypan blue (TB; Alchimia S.r.l, Austria). Subsequently, the corneal endothelium was washed with unsupplemented basal culture medium F99 (mixture of Ham F12 and Medium 199 in 1:1 ratio) or OptiMEM-I (Invitrogen by Life Technologies). The corneas were placed endothelial side up on corneal holders, and 0.5 mL basal culture medium was added to keep the endothelium moist. Peripheral DM and the trabecular meshwork margin were identified under a surgical microscope (Zeiss Lumera 300) and scored 360 degrees circumferentially using a Sinsky hook. Subsequently, the edge of DM was lifted off the posterior corneal stroma and manually peeled off centripetally with nontoothed surgical tissue holding forceps. Care was taken not to disturb the underlying stroma while scoring DM. The stroma was wiped with a sterile spear to ensure that all remaining DM was completely removed. Human corneas with an intact DM/endothelium complex were used as a positive control for normal CE function (group 1). CE cell density for group 1 (normal corneas) provided by the eye bank ranged from 1670 to 2200 cells/mm 2 with a mean of 2002 6 357 cells/mm 2 .
In Vitro Air Interface Corneal Organ Culture
Eye bank corneas were received under immersion organ culture conditions. However, for the experiments during which CE function was assessed, all corneas were maintained at 37°C, 5% CO 2 in a humidified incubator in in vitro airliquid interface organ culture, which allowed the corneas to be cultured under conditions that mimic normal physiological conditions under which the epithelial side of the cornea maintains contact with air (air-liquid interface). A Barron artificial anterior chamber was used, which consists of 3 parts: a base, a tissue holder, and a locking ring (Fig. 1) . The model allowed exchanging of culture medium by injection of fresh medium through the port connectors and also allowed controlled moisturizing of the epithelial side of the cornea.
Normal human corneas with an intact DM/endothelium complex (group 1), decompensated human corneas (group 2), and the cell therapy-treated groups 3 and 4 were cultured using the in vitro setup described above. Fresh culture medium prewarmed to 37°C was injected into the Barron artificial anterior chamber, and the epithelial side of the corneas was moistened with 200 mL of medium every hour and maintained in an incubator at 37°C (°C) and 5% carbon dioxide (CO 2 ) in a humidified environment. Central corneal thickness was measured using anterior segment optical coherence tomography (Zeiss Visante Germany) on an hourly basis for 12 hours and recorded for analysis. The corneas devoid of the DM/ endothelial complex were similarly mounted on chambers, and corneal thickness was measured over 12 hours.
Culture of an Immortalized hCEC Line HCEC-12
The HCEC-12 cell line, established in 1996 from normal CE cells of a 91-year-old white woman transformed with the early region of the simian virus 40 (SV40) genome including genes encoding the large T antigen and small t antigen, was obtained from the Leibniz Institute DSMZ (German collection of Microorganisms and Cell Cultures). 
Immunocytochemistry
HCEC-12 cells were cultured on chambered coverslips using F99 (Ham F12/Medium 199 1:1 mixture) and 8% FBS. Paraformaldehyde solution (10%) was used to fix the cells for 10 minutes at room temperature followed by a phosphatebuffered saline (PBS) wash. Blocking solution (10% FBS, 0.1% TritonX-100 in PBS) was added, and the cells were incubated for 1 hour at room temperature. Primary antibodies against Na + /K + ATPase and zonula occludens-1 (Abcam, Cambridge, United Kingdom) were diluted in blocking solution in a 1:100 dilution. The cells were incubated with the primary antibodies overnight at 4°C followed by a PBS wash. The secondary antibodies were diluted in blocking solution with Hoechst deoxyribonucleic acid stain and were incubated for 1 hour at room temperature. DAKO mounting medium was used to mount a coverslip.
Primary hCEC Isolation and Transplantation
The DM/endothelium complex from normal cadaveric human corneas (n = 5, mean age: 66 6 12 years; mean postmortem time: 51 6 7 days) was peeled as described in the section "CE decompensation model." After DM was peeled off, it was placed in a T25 tissue culture flask with 1 mL 0.05% trypsin/EDTA (Sigma-Aldrich, T3924). Primary hCECs were isolated by incubating for 15 to 20 minutes at 37°C and 5% CO 2 in a humidified incubator. Cell detachment was facilitated by tapping the flask gently and periodically. After the cells were completely dissociated from DM, 20 mL of OptiMEM-I supplemented with 8% FBS, 5 ng/mL epidermal growth factor (EGF), 20 mg/mL ascorbic acid, 200 mg/L calcium chloride, 0.08% chondroitin sulfate, and 50 mg/mL gentamicin were added to dilute and inhibit trypsin/ EDTA. The cells were then briefly pelleted by centrifugation and were then immediately seeded to the posterior stroma of group 4 donor corneas devoid of DM at a cell seeding density of 260,000 cells/200 mL per cornea (group 4).
Transplantation Procedure
Briefly, corneas devoid of DM were held in 50-mL centrifuge tubes with the posterior surface facing up, and the FIGURE 1. In vitro setup used for air interface corneal organ culture. All experiments were performed at air-liquid interface organ culture (OC) using the Barron artificial anterior chamber consisting of a base (1), tissue retainer (2), a locking ring (3), and pinch clamps (4) for opening and closing the perfusion tubes (purchased from Barron Precision Instruments) with a 12.5-mm opening, which allows the epithelial side of the cornea to be in contact with the air during organ culture in a humidified incubator at 37˚C, 5% CO 2 . primary and in vitro cultured hCECs were delivered to the posterior concavity in 200 mL of F99, 8% FBS (group 3), or OptiMEM-I supplemented with 8% FBS, 5 ng/mL EGF, 20 mg/mL ascorbic acid, 200 mg/L calcium chloride, 0.08% chondroitin sulfate, and 50 mg/mL gentamicin (group 4) at the defined seeding density. This setup was left undisturbed for 2 hours, after which the corneas were immersed in 20 mL of F99 (group 3) and OptiMEM-I (group 4) and incubated for 3 and 10 days, respectively. The proliferative capacity of primary CE cells was slower than that of the HCEC-12, and this was confirmed in in vitro culture by the observation of confluence intervals. Accordingly, experiments were tailored to allow sufficient time for primary CE to adhere and stabilize to the new substrate within 10 days compared with 3 days for HCEC-12-transplanted corneas. After this, the treated corneas were removed from the 50-mL centrifuge tubes and were mounted on the air-liquid interface model, with the epithelial surface facing up, and the endothelial surface was perfused with medium. Corneal thickness measurements were undertaken in the airinterface set-up and recorded at regular intervals for analysis.
Evaluation of Corneal Thickness Using Anterior Segment OCT
Zeiss Visante optical coherence tomography was used to scan the corneas and to acquire a cross-section image at specific orientations, ranging between 0 and 180 degrees, 45 and 225 degrees, 90 and 270 degrees, and 135 and 315 degrees. For each cornea, 7 individual measurements across a 6-mm diameter in the 4 above-mentioned orientations were completed. A total of 28 measurements were performed for each cornea at regular time intervals, and the average was calculated for analysis. All corneal thickness assessments were performed in the air-interface setup. . Optical coherence tomography revealed that both cell therapy groups 3 and 4 appeared similar in thickness to the normal corneas (group 1) and were significantly thinner compared with the decompensated corneas (group 2) (C). *Bonferroni corrected P , 0.004.
Histology
After each experiment, the human corneas were fixed in 10% formalin for 10 minutes at room temperature and were stored at 4°C for histological processing and hematoxylin and eosin (H&E) staining.
Statistical Analysis
The single-factor ANOVA test was used for statistical analysis to determine differences in corneal thickness measurements between corneal groups 1, 2, 3, and 4. Post hoc t tests (Bonferroni corrected) were used to compare corneal thickness of the different groups of corneas at specific time points throughout the incubation period. The error bars in graphs and bar charts represent mean 6 SD.
RESULTS
In Vitro Cultured hCEC
Before the cell transplantation phase, the HCEC-12 cells were tested for CE cell markers and showed positive Na + /K + ATPase and zonula occludens-1 expression (Fig. 2) .
Validation of the In Vitro Human Model of the CE Decompensation Model
Immediately after transfer into air-interface organ culture, initial thickness at time 0 for the normal corneas (n = 6) was 1092 6 108 mm and 1128 6 98 mm for the decompensated corneas (there was no statistically significant difference between the 2 groups at time point 0). After 12 hours in air-interface organ culture, the normal corneas showed a thickness decrease of 48% 6 9% from their initial value and reached a thickness of 557 6 72 mm. Thickness of the decompensated corneas (group 2), however, decreased by only 19% 6 10% from their initial thickness and maintained an edematous phenotype, with a mean thickness of 903 6 86 mm throughout the entire incubation period. The post hoc t test revealed that there was no statistically significant difference between the 2 groups at time point 0. However, there was a statistically significant difference between all other time points (Fig. 3) .
Posttransplantation Evaluation of Corneal Thickness
Decompensated corneas underwent cell therapy and were cultured for a period of 3 to 10 days. Initial corneal thickness measurements at time 0 for group 3 and group 4 FIGURE 4. Histology of hCEC transplantation to posterior corneal stroma of cadaveric human corneas. In group 3, a CE cell monolayer was present 3 days after transplantation (A) (H&E staining; ·400). In group 4, a CE cell monolayer was seen established at 10 days with primary hCECs (B). The donor epithelium was intact in all corneas, and both control and study corneas underwent the same management for corneal epithelial protection (C) [hematoxylin and eosin (H&E) staining; ·400]. Group 3 and group 4 had an average cell density of 1925 6 178 cells/mm 2 and 2000 6 212 cells/mm 2 , respectively, (D) (alizarin red staining; ·200) and (E) (phase contrast; ·200). The area of each individual square in D and E is 0.01 mm 2 , and the red dots represent the cell number in each square. corneas were 1218 6 153 mm and 1100 6 86 mm, respectively (P , 0.0001). At the end of the 12-hour incubation, group 3 had an average thickness of 458 6 90 mm (63% 6 6% decrease), and group 4 had a thickness of 489 6 94 mm (55% 6 7% decrease from its initial thickness). Stromal thickness had reduced significantly after cell therapy in decompensated corneas from baseline thickness (group 3: P , 0.0001 and group 4: P , 0.0001), and there was no significant difference between group 3 and group 4 corneas in relation to stromal thickness at their corresponding endpoints (Fig. 3) .
Endothelial Cell Attachment and Formation of Cell Monolayer After Cell Transplantation
In corneas treated with hCECs and HCEC-12 (groups 3 and 4), the transplanted cells formed a monolayer on the posterior stromal surface with cell attachment, and the donor epithelium was present in all corneas. Care was taken to avoid any trauma or abrasion during experimentation and in the artificial anterior chamber where regular lubrication was provided to the corneal surface (Fig. 4) . 
DISCUSSION
It has been demonstrated experimentally that a Na + /K + ATPase performs the active transport in the CE, 34, 35 whereas tight junctions and adherens junctions play a role in its barrier function, which limits paracellular fluid leak from the aqueous to the stroma. The integrity of the barrier and pump function of the CE helps maintain the stroma in a dehydrated state. 36 Because the CE barrier and pump function could not be directly tested, corneal deswelling and the change in thickness were used as a surrogate measure of CE barrier and pump function combined with a histological evaluation of cell attachment.
Studies that used human donor corneas with intact DM for hCEC transplantation testing reported that at seeding densities of 50,000, 150,000, and 700,000 cells per cornea, an endothelial cell density of 1800 to 2200 cells/mm 2 was attainable; in addition, 20 days after transplantation, the corneas showed a significant decrease in thickness and maintained near-physiological thickness of around 700 mm after perfusion culture over an incubation period of 8 to 24 hours. [25] [26] [27] [28] Another study that tested hCEC transplantation using in vitro cultured human donor corneas denuded of their native endothelium but still with intact DM reported that at seeding densities of between 250,000 and 500,000 cells, a posttransplantation average cell density of 1895 6 178 cells/mm 2 was achieved 7 to 14 days after transplantation. 29 In our study, all recipient corneas had their DM removed from the edge of the Schlemm canal, and we used a seeding density of 310,000 cells/200 mL and 260,000 cells/ 200 mL per cornea for the HCEC-12 cells and the primary hCECs, respectively, and achieved posttransplantation endothelial cell density of 1925 6 178 cells/mm 2 and 2000 6 212 cells/mm 2 and thicknesses of 458 6 90 mm and 489 6 94 mm, respectively, after a 12-hour air-interface organ culture incubation period. Figure 4 shows the transplanted CE cells attached to the posterior corneal stroma in the absence of DM. Focal detachment and vacuolation of the CE cells may represent degenerative changes occurring in the culture medium and/or as a result of histological processing. Similarly, although the epithelium is adherent, the lack of multilayered epithelium is a limitation in in vitro models. However, evaporation from the anterior surface of the cornea is likely to have contributed to the overall reduction in stromal thickness observed in our study. The dehydration effect was observed in group 2 corneas and the study group (groups 3 and 4). However, the corneas that underwent endothelial cell therapy demonstrated recovery of physiological thickness compared with group 2 that lacked the endothelial cell layer, highlighting the importance of a functioning endothelial cell layer in maintenance of corneal thickness and transparency in our model. It is worth noting that HCEC-12 being an immortalized cell line would not be directly applicable for clinical therapy.
In our study, after transplantation, the corneal endothelium was cultured in F99, 8% FBS (for group 3), or OptiMEM-I supplemented with 8% FBS, 5 ng/mL EGF, 20 mg/mL ascorbic acid, 200 mg/L calcium chloride, 0.08% chondroitin sulfate, and 50 mg/mL gentamicin (for group 4). Because experiments for testing the CE cell function were done over a short period of 12 hours, this protocol was used for consistency and to minimize the change of culture medium from cell culture to the transplant model. This, however, would have acted as a stimulant for further CE proliferation, which is not desirable posttransplantation. Therefore, we would aim to reconsider this protocol for future experiments and in planning in vivo human clinical trials.
In addition, refinement to in vitro culture of hCECs, methods of delivery, and longer-term studies related to cell fate and proliferation posttransplantation would be vital to add to the translational value of cell-based therapy in corneal disorders. The short-term nature of the observation and the lack of immunity-related factors are the limitations of this in vitro setup. Nevertheless, the results are encouraging, and we were able to demonstrate the functional potential of the cell-based approach in the controlled environment used in our experiments. The results of this study corroborated with previously reported results [25] [26] [27] [28] [29] [30] and demonstrated that after hCEC transplantation directly to the corneal stroma, similar results were obtained in comparison to hCEC transplantation to DM.
In conclusion, this study tested the stromal hydration behavior of normal and decompensated human corneas in the air-liquid interface organ culture. The edematous phenotype of corneas denuded of their DM/endothelium complex established an experimental corneal decompensation model. Using this in vitro model, it was demonstrated that direct transfer of primary hCECs and cultured HCEC-12 to the posterior corneal stroma could result in a functional endothelial cell monolayer similar to normal corneas, thus demonstrating the feasibility of the cell-based approach to treat CE disorders in humans.
